Showing 1921-1930 of 2658 results for "".
- Corxel and Lenz Therapeutics Announce Positive Phase 3 Trial Results for Presbyopia Eye Drop LNZ100 in Chinahttps://modernod.com/news/corxel-pharmaceuticals-and-lenz-therapeutics-announce-positive-phase-3-trial-results-for-presbyopia-eye-drop-lnz100-in-china/2482519/Lenz Therapeutics and its parner Corxel Pharmaceuticals unveiled phase 3 trial results from the China-based JX07001 study, showing that LNZ100, an aceclidine-based eye drop, achieved significant improvement in near vision for presbyopia patients. The study's topline results demonstr
- Cathleen McCabe, MD, Appointed Strategic Medical Advisor at Bausch + Lombhttps://modernod.com/news/cathleen-mccabe-md-appointed-strategic-medical-advisor-at-bausch-lomb/2482507/Bausch + Lomb has appointed Cathleen McCabe, MD, as Strategic Medical Advisor. According to B+L, in this new consultancy role, Dr. McCabe will contribute her expertise to Bausch + Lomb’s product portfolio expansion and collaborate with the research and development team to drive in
- Ripple Therapeutics Announces Evaluation and Licensing Agreements with Glaukoshttps://modernod.com/news/ripple-therapeutics-announces-evaluation-and-licensing-agreements-with-glaukos/2482502/Ripple Therapeutics announced a new evaluation and licensing agreement with Glaukos this week that aims to leverage Ripple’s patented technology platform to create sustained release implants of targeted therapeutics for both glaucoma and retinal diseases. Financial terms of the de
- Johnson & Johnson to Showcase Tecnis Odyssey IOL and Present New Research at AAO 2024https://modernod.com/news/johnson-johnson-to-showcase-tecnis-odyssey-iol-and-present-new-research-at-aao-2024/2482501/Johnson & Johnson will highlight its latest innovations in eye health during the 2024 American Academy of Ophthalmology (AAO) annual meeting, taking place from October 18-21 in Chicago. Among the company's spotlight advancements is the Tecnis Odyssey IOL, a new presbyopia-correcting IOL t
- Alcon Collaborates with Eye Care Professionals to Identify and Address Unmet Needs in the Contact Lens Industryhttps://modernod.com/news/alcon-collaborates-with-eye-care-professionals-to-identify-and-address-unmet-needs-in-the-contact-lens-industry/2482485/A new Alcon program aims to identify and address current gaps in contact lens offerings by partnering with eye care professionals. With the new Alcon Innovator Program, 20 ‘innovators’ were selected to receive and offer their patients exclusive access to Alcon’s upcoming product
- Melt Announces Completion of Patient Dosing in Phase 3 Study of MELT-300 for Procedural Sedationhttps://modernod.com/news/melt-pharmaceuticals-announces-completion-of-patient-dosing-in-phase-3-study-of-melt-300-for-procedural-sedation/2482477/Melt Pharmaceuticals announced the completion of patient dosing in its pivotal phase 3 clinical trial. This study evaluates the safety and efficacy of MELT-300, the company's lead product candidate, for providing non-intravenous, non-opioid sedation during cataract surgery. MELT-300
- Novaliq and Laboratoires Théa Announce EU Approval for Vevizye for Dry Eye Diseasehttps://modernod.com/news/novaliq-and-laboratoires-thea-announce-partnership-and-eu-approval-for-vevizye/2482466/Novaliq and Laboratoires Théa announced the European Commission’s approval of Vevizye (ciclosporin 0.1% eye drops solution) for the treatment of moderate to severe dry eye disease (DED) in adults unresponsive to tear substitutes. Vevizye is based on Nova
- Bausch + Lomb Launches Opal Digital Marketplace in the UShttps://modernod.com/news/bausch-lomb-launches-opal-digital-marketplace-in-the-us/2482465/Bausch + Lomb announced the US launch of Opal, a new digital e-commerce marketplace designed to enhance efficiency for eye care practices while improving the patient experience. The platform provides a streamlined and user-friendly ordering process for Bausch + Lomb’s contact lens
- Andreas Pecher to Succeed Dr. Karl Lamprecht as President and CEO of Carl Zeiss AGhttps://modernod.com/news/andreas-pecher-to-succeed-dr-karl-lamprecht-as-president-and-ceo-of-carl-zeiss-ag/2482461/After nearly two decades of leadership at Carl Zeiss AG, Karl Lamprecht, the current President and CEO, has announced that he will not be extending his contract, which is set to expire in the spring of 2025. Andreas Pecher was appointed the company's new President and CEO, effective Apri
- Aviceda Completes Enrollment for Phase 2b SIGLEC Study for Geographic Atrophy Treatmenthttps://modernod.com/news/aviceda-completes-enrollment-for-phase-2b-siglec-study-for-geographic-atrophy-treatment/2482456/Aviceda Therapeutics announced the completion of patient enrollment for its phase 2b SIGLEC study. The trial is comparing the safety and efficacy of the company's lead candidate, AVD-104, with avacincaptad pegol (marketed as Izervay) for the treatment of geographic atrophy (GA) secondary to a